CIK 0001880438
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
AN2 Therapeutics, Inc.
Sign in to watch- Ticker
- ANTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 820606654
- Phone
- +1 650-331-9090
- Business address
- 1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA, 94025
- Open-market buys, last 90 days
- $11,602
- in 1 filing
- Open-market sales, last 90 days
- $117,428
- in 4 filings, $104K under 10b5-1 plans
Net −$105,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-16 | Aziz Kabeer Director | Sale | −15,907 | $19.65 | $313K | 377,542 |
| 2024-01-16 | Adjuvant Global Health Technology Fund, L.P. 10% owner | Sale | −84,093 | $19.65 | $1.7M | 1,995,958 |
| 2024-01-16 | Adjuvant Global Health Technology Fund, L.P. 10% owner | Sale | −15,907 | $19.65 | $313K | 377,542 |
| 2024-01-12 | Readnour Robin Shane Director | Sale 10b5-1 | −706 | $21.92 | $15K | 414,788 |
| 2024-01-12 | Readnour Robin Shane Director | Sale 10b5-1 | −719 | $21.91 | $16K | 485,073 |
| 2024-01-10 | Readnour Robin Shane Director | Sale 10b5-1 | −1,869 | $21.93 | $41K | 415,494 |
| 2024-01-10 | Readnour Robin Shane Director | Sale 10b5-1 | −1,800 | $21.92 | $39K | 485,792 |
| 2024-01-09 | Krause Kevin Michael Chief Strategy Officer | Exercise or conversion 10b5-1 | +2,417 | $0.42 | $1K | 4,331 |
| 2024-01-09 | Krause Kevin Michael Chief Strategy Officer | Exercise or conversion 10b5-1 | +5,000 | $6.60 | $33K | 9,331 |
| 2024-01-09 | Krause Kevin Michael Chief Strategy Officer | Sale 10b5-1 | −7,417 | $20.14 | $149K | 1,914 |
| 2024-01-09 | Krause Kevin Michael Chief Strategy Officer | Exercise or conversion · Stock Option (right to buy) 10b5-1 | −2,417 | 49,868 | ||
| 2024-01-09 | Krause Kevin Michael Chief Strategy Officer | Exercise or conversion · Stock Option (right to buy) 10b5-1 | −5,000 | 26,832 | ||
| 2024-01-02 | Krause Kevin Michael Chief Strategy Officer | Exercise or conversion 10b5-1 | +2,583 | $0.42 | $1K | 4,497 |
| 2024-01-02 | Krause Kevin Michael Chief Strategy Officer | Sale 10b5-1 | −2,583 | $20.12 | $52K | 1,914 |
| 2024-01-02 | Krause Kevin Michael Chief Strategy Officer | Exercise or conversion · Stock Option (right to buy) 10b5-1 | −2,583 | 52,285 | ||
| 2024-01-02 | Easom Eric Chief Executive Officer | Sale 10b5-1 | −2,777 | $20.09 | $56K | 2,130 |
| 2023-11-14 | Adjuvant Global Health Technology Fund, L.P. 10% owner | Sale 10b5-1 | −1,522 | $16.15 | $25K | 2,080,051 |
| 2023-11-14 | Adjuvant Global Health Technology Fund, L.P. 10% owner | Sale 10b5-1 | −288 | $16.15 | $5K | 393,449 |
| 2023-11-14 | Aziz Kabeer Director | Sale 10b5-1 | −1,522 | $16.15 | $25K | 2,080,051 |
| 2023-11-14 | Aziz Kabeer Director | Sale 10b5-1 | −288 | $16.15 | $5K | 393,449 |
Page 12 of 20 · 385 trades